



6<sup>th</sup> Edition

# DRUG PRICING TRANSPARENCY CONGRESS

March 30-31, 2020 • Inn at Penn, a Hilton Hotel • Philadelphia, PA

## High-Impact Topics Transforming Pricing Dynamics:

- Stay on the pulse of evolving drug pricing transparency legislation and litigation
- Explore how the future of pricing transparency requirements will impact commercialization, reimbursement and drug pricing models
- Deliver comprehensive legal interpretations of drug pricing transparency and reporting laws currently on the books and the policy outlook for 2020 and beyond
- Benchmark overall state compliance practices related to drug pricing reporting
- Discuss organizational shifts within legal and compliance departments to handle drug pricing obligations and reporting

## New Features for 2020:

Extended  
State-by-State  
Analysis Showcase

Exclusive Benchmarking  
Report — Industry  
Intelligence on  
Managing Transparency  
Requirements

Customizable  
Programming with  
4 In-Depth Topic  
Intensives

Interactive Breakouts  
Based on  
Company Type

**CBI**  
an informa business

 CBI PRICING &  
CONTRACTING SERIES

[WWW.CBINET.COM/DRUGPRICING](http://WWW.CBINET.COM/DRUGPRICING)

# ABOUT THE CONFERENCE

With the recent flurry of regulatory activity surrounding drug pricing transparency, bio/pharma manufacturers must continuously be ahead of the ever-evolving changes. Join **CBI's Drug Pricing Transparency Congress** to discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Assess how companies are planning internally for these changes and gain a preview of what's to come in 2020.

ine News **Headline News** Headline News Headline News Headline Ne

**Pelosi's Drug Plan Would Let U.S. Negotiate Prices of 250 Medications**

— The New York Times – Sept. 19, 2019

**Nevada fines 21 companies for not providing drug-pricing data.**

— STAT News – Oct. 3, 2019

**This year alone 51 bills dealing with drug cost transparency were introduced in state legislatures.**

— BIOPHARMA DIVE – Sept. 23, 2019

## OUR CORE AUDIENCE

Pharmaceutical, medical device, or biotechnology companies with responsibilities in:



## SEE WHO BENEFITTED FROM ATTENDING IN 2019



- 41% Pricing/Contracting
- 20% Government Affairs
- 14% Counsel/Legal
- 11% Access/Commercial Affairs
- 7% Compliance
- 7% Finance

# DAY ONE MONDAY, MARCH 30, 2020

7:30 *Conference Registration and Networking Breakfast*

8:30 *Chairman's Opening Remarks*

## State Transparency Reporting Requirements Showcase

8:45 **Drug Pricing Transparency State of The Industry**

9:30 **Unpack Price Increase Transparency Requirements**

10:30 *Networking and Refreshment Break*

11:00 **Update on the Price Increase Advance Notice Requirements**

12:00 *Networking Luncheon*

1:15 **Status Report on New Drug Pricing Reporting Requirements**

2:15 **Analyze Price Disclosure Requirements to Health Care Providers (HCPs)**

2:45 *Networking and Refreshment Break*

3:15 **Ask the Experts Panel Discussion**

4:15 **BIO and PhRMA Address • Keeping a Pulse on New Legislation and Current Industry Efforts**

5:15 *Close of Day One | Networking, Wine and Cheese Reception Commences*

# DAY TWO TUESDAY, MARCH 31, 2020

8:00 *Networking Breakfast*

8:30 *Chairman's Review of Day One*

8:45 **View from the Hill – Federal Initiatives for Transparency**

9:45 **Industry Pulse – Benchmarking Survey Results Revealed**

10:15 *Networking and Refreshment Break*

## Best Practices to Operationalize Transparency Requirements

10:45 **Panel Discussion • Keys for Success and Traps for the Unwary – A Roadmap for Compliance**

11:45 **How to go from Reactive to Proactive When It Comes to Transparency Laws**

12:30 *Networking Luncheon*

1:30 **Compliance Spotlight • Trends in Drug Transparency Enforcement and Oversight**

2:15 **Safeguarding Your Most Sensitive Information – Intersection of Transparency Legislation and Trade Secret Law**

3:00 *Close of Conference*

# THOUGHT LEADERS DRIVING THE DIALOGUE IN 2019



Bill Harris,  
Assistant General Counsel, US Market Access,  
**Sanofi**



Debbie Walters-Francique,  
Vice President, Assistance General Counsel,  
**Pfizer Inc**



John Oroho,  
EVP & Chief Strategy Officer,  
**Porzio Life Sciences LLC**



Trevor Wear,  
Partner,  
**Sidley Austin LLP**



Brian Bohnenkamp,  
Partner FDA & Life Sciences Practice,  
**King & Spalding LLP**



Merlin Brittenham,  
Senior Dir Law,  
**PhRMA**



Jack Chen,  
Associate,  
**Sidley Austin LLP**



Rujul Desai,  
Counsel,  
**Covington & Burling LLP**



Thomas Felton,  
Senior Corporate Counsel,  
**Celgene**



Austin Hay,  
Managing Consultant,  
**Berkeley Research Group**



John Linehan,  
Member of the Firm,  
**Epstein Becker & Green**



Mallory O'Connor,  
Director Public Policy,  
**Mallinckrodt Pharmaceuticals**



Saumil Pandya,  
Deputy VP Advocacy & Strategic Alliances,  
**PhRMA**



Bill Sarraile,  
Partner,  
**Sidley Austin LLP**



Christopher Smith,  
Sr Counsel,  
**Epstein Becker & Green**



Sheea Sybblis,  
Senior Counsel,  
**Boehringer Ingelheim Pharmaceuticals Inc**



Alyson Wooten,  
Director,  
**Berkeley Research Group**



Charles Fournier,  
VP Policy & Advocacy,  
**Type 1 Diabetes Defense Foundation**



David Gibbons,  
Associate,  
**Hyman Phelps & McNamara PC**



Susan Hibbard,  
Associate Director Compliance & Transparency,  
**Boehringer Ingelheim**



James Kim,  
Attorney,  
**McDermott Will & Emery**



Kendra Martello, Executive Director Public  
Policy & Corporate Social Responsibility,  
**Mallinckrodt Pharmaceuticals**



John Murphy III,  
Deputy General Counsel,  
**Biotechnology Innovation Organization**



Amie Phillips Pablo,  
Director Government Reporting,  
**Novo Nordisk**



Satish Pandelenghat,  
Digital Strategist,  
**DXC Technology**



Vincent Sampson,  
Special Counsel,  
**Cooley LLP**



Manjunath Shanabag,  
Digital General Manager,  
**DXC Technology**



Prasun Subedi,  
Senior Director Patient & Health Impact,  
**Pfizer Inc**



Keren Tenebaum,  
Assistant General Counsel,  
**Pfizer Inc**



Stephanie Trunk,  
Partner,  
**Arent Fox LLP**



# PREVIOUS ATTENDEE ACCLAIM

"CBI's 5th Edition Drug Pricing Transparency Congress provided a comprehensive review of key laws already implemented as well as soon-to-be implemented laws. Also, gaining insight from industry lessons learned was extremely beneficial to my state reporting role within my organization. Engaging with the presenters and attendees was a great way to network and benchmark our current practices."

— Senior Specialist State Reporting Operations, Sanofi

"Overall conference was very informative and relevant to the reporting landscape companies are working on and the outlook of what legislation is coming down the road was valuable."

— Anonymous

"CBI's Drug Pricing Conference helps you keep up to the date on the latest developments in drug pricing."

— Vice President and Assistant General Counsel, Pfizer Inc

"Very informative — nice location — great speakers as well with really good presentations."

— Anonymous

"Had a great experience at the workshop and conference, especially the lessons learned and industry feedback on reporting to states. These experiences are invaluable and any way to include more in the conference would be an added benefit to all attendees."

— Anonymous

"Informative discussions to help industry prepare for implementation of the new regulations applicable to the pharmaceutical industry."

— Director, Ethics & Compliance, Novo Nordisk

## HOW YOU'LL CONNECT...

Reach Out to the **Drug Pricing Transparency Congress** Team to Get Involved:

### SPEAKING OPPORTUNITIES:



**Jordan Simmons**

jordan.simmons@informa.com  
339-298-2230

### SPONSORSHIP OPTIONS:



**Derek Tagliarino**

derek.tagliarino@informa.com  
339-298-2206

### REGISTRATION & TEAMS:



**Matt Hannon**

matt.hannon@informa.com  
339-298-2157

